Outcome measurement in economic evaluations of growth factors
- PMID: 7508726
- DOI: 10.1016/0959-8049(93)90612-j
Outcome measurement in economic evaluations of growth factors
Abstract
There are several ways of measuring outcome in an economic evaluation of filgrastim therapy. These measures imply different types of economic evaluation. In all cases, the filgrastim therapy is compared with no filgrastim therapy. Since different therapeutic strategies are connected with uncertain consequences, decision trees are helpful analytical tools. The potential implications of different types of economic evaluations are illustrated with a simple decision tree.
Similar articles
-
Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.Formulary. 1995 Jul;30(7):394-5, 400-4. Formulary. 1995. PMID: 10151731
-
Using filgrastim efficiently.Pharmacoeconomics. 1996 May;9(5):466-8. doi: 10.2165/00019053-199609050-00009. Pharmacoeconomics. 1996. PMID: 10161379 No abstract available.
-
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.Eur J Cancer. 1993;29A Suppl 7:S23-30. doi: 10.1016/0959-8049(93)90613-k. Eur J Cancer. 1993. PMID: 7508727 Clinical Trial.
-
Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.Pharmacoeconomics. 1994;6 Suppl 2:18-26. doi: 10.2165/00019053-199400062-00005. Pharmacoeconomics. 1994. PMID: 10155592 Review.
-
[Myeloid growth factors. New indications with many questions].Lakartidningen. 1994 Jul 13;91(28-29):2675-8. Lakartidningen. 1994. PMID: 7519704 Review. Swedish. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources